STAT3 decoy oligodeoxynucleotides-loaded solid lipid nanoparticles induce cell death and inhibit invasion in ovarian cancer cells

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Ma, Yanhui ^a   Zhang, Xiaolei ^a   Xu, Xiaoxuan ^a   Shen, Liang ^b   Yao, Yao ^b   Yang, Ziyan ^a   Liu, Peishu ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BECLIN 1; DECOY OLIGODEOXYNUCLEOTIDE; GELATINASE B; MAMMALIAN TARGET OF RAPAMYCIN; OLIGODEOXYNUCLEOTIDE; PROCASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; SOLID LIPID NANOPARTICLE; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; ANTISENSE OLIGONUCLEOTIDE; CADHERIN; CASPASE 3; INHIBITOR OF APOPTOSIS PROTEIN; NANOPARTICLE; TRANSCRIPTION FACTOR;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER GENE THERAPY; CANCER INHIBITION; CELL DEATH; CELL INVASION; CELL VIABILITY; CONTROLLED STUDY; ENCAPSULATION; HUMAN; HUMAN CELL; MIGRATION INHIBITION; OVARIAN CANCER CELL LINE; PROTEIN EXPRESSION; UPREGULATION; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL PROLIFERATION; CHEMISTRY; DOWN REGULATION; FEMALE; GENE TRANSFER; GENETICS; METABOLISM; OVARY TUMOR; PATHOLOGY; TRANSMISSION ELECTRON MICROSCOPY; TUMOR CELL LINE;

GASTROPODA;

APOPTOSIS; AUTOPHAGY; CADHERINS; CASPASE 3; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MATRIX METALLOPROTEINASE 9; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; SNAIL FAMILY TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; UP-REGULATION;

EID: 84928815236     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124924     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62:10-29. doi: 10. 3322/caac.20138 PMID: 22237781
2. Chobanian N, Dietrich CS 3rd. Ovarian cancer. Surg Clin North Am. 2008; 88:285-299, vi. doi: 10.1016/j.suc.2007.12.002 PMID: 18381114
3. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J. Gene therapy clinical trials worldwide to 2012-an update. J Gene Med. 2013; 15:65-77. doi: 10.1002/jgm.2698 PMID: 23355455
4. Brenner MK, Okur FV. Overview of gene therapy clinical progress including cancer treatment with gene-modified T cells. Hematology Am Soc Hematol Educ Program. 2009:675-681. doi: 10.1182/asheducation-2009.1.675 PMID: 20008253
5. Assi H, Candolfi M, Baker G, Mineharu Y, Lowenstein PR, Castro MG. Gene therapy for brain tumors: basic developments and clinical implementation. Neurosci Lett. 2012; 527:71-77. doi: 10.1016/j.neulet.2012.08.003 PMID: 22906921
6. Keeler AM, Flotte TR. Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome. Hum Gene Ther. 2012; 23:548-556. doi: 10.1089/hum.2012.087 PMID: 22642257
7. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999; 98:295-303. PMID: 10458605
8. Huang M, Page C, Reynolds RK, Lin J. Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol. 2000; 79:67-73. PMID: 11006034
9. Burke WM, Jin X, Lin HJ, Huang M, Liu R, Reynolds RK, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene. 2001; 20:7925-7934. PMID: 11753675
10. Savarese TM, Campbell CL, McQuain C, Mitchell K, Guardiani R, Quesenberry PJ, et al. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas. Cytokine. 2002; 17:324-334. PMID: 12061840
11. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res. 2004; 64:3550-3558. PMID: 15150111
12. Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, et al. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer. Clin Cancer Res. 2006; 12:5055-5063. PMID: 16951221
13. Deng J, Liu Y, Lee H, Herrmann A, Zhang W, Zhang C, et al. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites. Cancer Cell. 2012; 21:642-654. doi: 10.1016/j.ccr.2012.03.039 PMID: 22624714
14. Nefedova Y, Gabrilovich DI. Targeting of Jak/STAT pathway in antigen presenting cells in cancer. Curr Cancer Drug Targets. 2007; 7:71-77. PMID: 17305479
15. Klein JD, Sano D, Sen M, Myers JN, Grandis JR, Kim S. STAT3 oligonucleotide inhibits tumor angiogenesis in preclinical models of squamous cell carcinoma. PLoS One. 2014; 9:e81819. doi: 10.1371/journal.pone.0081819 PMID: 24404126
16. Gu J, Li G, Sun T, Su Y, Zhang X, Shen J, et al. Blockage of the STAT3 signaling pathway with a decoy oligonucleotide suppresses growth of human malignant glioma cells. J Neurooncol. 2008; 89:9-17. doi: 10.1007/s11060-008-9590-9 PMID: 18415045
17. Sun X, Zhang J, Wang L, Tian Z. Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN. Cancer Lett. 2008; 262:201-213. doi: 10.1016/j.canlet.2007.12.009 PMID: 18248786
18. Souissi I, Najjar I, Ah-Koon L, Schischmanoff PO, Lesage D, Le Coquil S, et al. A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-kappaB. BMC Cell Biol. 2011; 12:14. doi: 10.1186/1471-2121-12-14 PMID: 21486470
19. Anderson WF. Human gene therapy. Nature. 1998; 392:25-30. PMID: 9579858
20. Han S, Mahato RI, Sung YK, Kim SW. Development of biomaterials for gene therapy. Mol Ther. 2000; 2:302-317. PMID: 11020345
21. Pedroso de Lima MC, Simoes S, Pires P, Faneca H, Duzgunes N. Cationic lipid-DNA complexes in gene delivery: from biophysics to biological applications. Adv Drug Deliv Rev. 2001; 47:277-294. PMID: 11311996
22. Merdan T, Kopecek J, Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev. 2002; 54:715-758. PMID: 12204600
23. Muller RH, Mader K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000; 50:161-177. PMID: 10840199
24. Tabatt K, Sameti M, Olbrich C, Muller RH, Lehr CM. Effect of cationic lipid and matrix lipid composition on solid lipid nanoparticle-mediated gene transfer. Eur J Pharm Biopharm. 2004; 57:155-162. PMID: 15018970
25. Yu W, Liu C, Ye J, Zou W, Zhang N, Xu W. Novel cationic SLN containing a synthesized single-tailed lipid as a modifier for gene delivery. Nanotechnology. 2009; 20:215102. doi: 10.1088/0957-4484/20/21/215102 PMID: 19423923
26. Zhang X, Liu P, Zhang B, Wang A, Yang M. Role of STAT3 decoy oligodeoxynucleotides on cell invasion and chemosensitivity in human epithelial ovarian cancer cells. Cancer Genet Cytogenet. 2010; 197:46-53. doi: 10.1016/j.cancergencyto.2009.10.004 PMID: 20113836
27. Ye J, Wang A, Liu C, Chen Z, Zhang N. Anionic solid lipid nanoparticles supported on protamine/DNA complexes. Nanotechnology. 2008; 19:285708. doi: 10.1088/0957-4484/19/28/285708 PMID: 21828742
28. Zhang X, Liu P, Zhang B, Mao H, Shen L, Ma Y. Inhibitory effects of STAT3 decoy oligodeoxynucleotides on human epithelial ovarian cancer cell growth in vivo. Int J Mol Med. 2013; 32:623-628. doi: 10.3892/ijmm.2013.1431 PMID: 23828376
29. Shi S, Han L, Gong T, Zhang Z, Sun X. Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew Chem Int Ed Engl. 2013; 52:3901-3905. doi: 10.1002/anie.201208077 PMID: 23450685
30. Olbrich C, Bakowsky U, Lehr CM, Muller RH, Kneuer C. Cationic solid-lipid nanoparticles can efficiently bind and transfect plasmid DNA. J Control Release. 2001; 77:345-355. PMID: 11733101
31. del Pozo-Rodriguez A, Delgado D, Solinis MA, Gascon AR, Pedraz JL. Solid lipid nanoparticles: formulation factors affecting cell transfection capacity. Int J Pharm. 2007; 339:261-268. PMID: 17467205
32. Basarkar A, Devineni D, Palaniappan R, Singh J. Preparation, characterization, cytotoxicity and transfection efficiency of poly(DL-lactide-co-glycolide) and poly(DL-lactic acid) cationic nanoparticles for controlled delivery of plasmid DNA. Int J Pharm. 2007; 343:247-254. PMID: 17611054
33. Yuan Q, Han J, Cong W, Ge Y, Ma D, Dai Z, et al. Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicity. Int J Nanomedicine. 2014; 9:4829-4846. doi: 10.2147/IJN.S70919 PMID: 25378924
34. Shi SJ, Zhong ZR, Liu J, Zhang ZR, Sun X, Gong T. Solid lipid nanoparticles loaded with anti-microRNA oligonucleotides (AMOs) for suppression of microRNA-21 functions in human lung cancer cells. Pharm Res. 2012; 29:97-109. doi: 10.1007/s11095-011-0514-6 PMID: 21732152
35. Schubert MA, Muller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm. 2005; 61:77-86. PMID: 16011893
36. Cortesi R, Campioni M, Ravani L, Drechsler M, Pinotti M, Esposito E. Cationic lipid nanosystems as carriers for nucleic acids. N Biotechnol. 2014; 31:44-54. doi: 10.1016/j.nbt.2013.10.001 PMID: 24120492
37. Heydenreich AV, Westmeier R, Pedersen N, Poulsen HS, Kristensen HG. Preparation and purification of cationic solid lipid nanospheres-effects on particle size, physical stability and cell toxicity. Int J Pharm. 2003; 254:83-87. PMID: 12615415
38. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials. 2003; 24:1121-1131. PMID: 12527253
39. Ghobrial IM, Witzig TE, Adjei AA. Targeting apoptosis pathways in cancer therapy. CA Cancer J Clin. 2005; 55:178-194. PMID: 15890640
40. Kamada S, Kikkawa U, Tsujimoto Y, Hunter T. Nuclear translocation of caspase-3 is dependent on its proteolytic activation and recognition of a substrate-like protein(s). J Biol Chem. 2005; 280:857-860. PMID: 15569692
41. Giraud AS, Menheniott TR, Judd LM. Targeting STAT3 in gastric cancer. Expert Opin Ther Targets. 2012; 16:889-901. doi: 10.1517/14728222.2012.709238 PMID: 22834702
42. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov. 2007; 6:304-312. PMID: 17396135
43. Tanida I, Ueno T, Kominami E. LC3 conjugation system in mammalian autophagy. Int J Biochem Cell Biol. 2004; 36:2503-2518. PMID: 15325588
44. Jonchere B, Belanger A, Guette C, Barre B, Coqueret O. STAT3 as a new autophagy regulator. JAKSTAT. 2013; 2:e24353. doi: 10.4161/jkst.24353 PMID: 24069557
45. Caldera V, Mellai M, Annovazzi L, Valente G, Tessitore L, Schiffer D. Stat3 expression and its correlation with proliferation and apoptosis/autophagy in gliomas. J Oncol. 2008; 2008:219241. doi: 10.1155/2008/219241 PMID: 19421400
46. Garg M. Epithelial-mesenchymal transition-activating transcription factors-multifunctional regulators in cancer. World J Stem Cells. 2013; 5:188-195. doi: 10.4252/wjsc.v5.i4.188 PMID: 24179606
47. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat Rev Cancer. 2004; 4:118-132. PMID: 14964308
48. Kim MJ, Lim J, Yang Y, Lee MS, Lim JS. N-myc downstream-regulated gene 2 (NDRG2) suppresses the epithelial-mesenchymal transition (EMT) in breast cancer cells via STAT3/Snail signaling. Cancer Lett. 2014; 354:33-42. doi: 10.1016/j.canlet.2014.06.023 PMID: 25153349
49. Lee MY, Shen MR. Epithelial-mesenchymal transition in cervical carcinoma. Am J Transl Res. 2012; 4:1-13. PMID: 22347518